Sangui BioTech International, Inc.
Sangui Biotech International, Inc. (SGBI) is a publicly held company engaged in the development of pharmaceutical, medical and cosmetic products. The company operates the business through its wholly owned subsidiaries, including, Sangui BioTech, Inc. (SBT), SanguiBioTech AG, GlukoMediTech AG, and Sangui Biotech Singapore Pte Ltd. The company also operates in Europe through its subsidiary, Sangui BioTech GmbH, which is engaged in the research, development, manufacture, and sale of medical products. SGBI principally focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and chronic lack of oxygen due to arterial occlusion, anaemia or blood loss caused by surgery or trauma. In addition, Sangui BioTech developed external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays used for the healing chronic wounds as well as gels and emulsions for the regeneration of the skin. Further, SanguiBioTech has developed HEMO2SPRAY, a haemoglobin spray which apparently has a significant positive effect on wound healing and Pure Mo2isture, a micro-emulsion which penetrates the stratum corneum enabling an increased afflux of oxygen from the air; as well as Chitoskin wound pads. SGBI is headquartered in Witten, Germany.